Literature DB >> 32224703

Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases.

Jacob J Rozich1, Ariela Holmer2, Siddharth Singh2,3.   

Abstract

Various lifestyle factors including physical activity and obesity, stress, sleep, and smoking may modify the risk of developing inflammatory bowel diseases (IBDs). In patients with established IBD, these lifestyle factors may significantly impact the natural history and clinical outcomes. Recreational exercise decreases the risk of flare and fatigue in patients with IBD. In contrast, obesity increases the risk of relapse and is associated with higher anxiety, depression, fatigue, and pain and higher health care utilization. Obesity also modifies pharmacokinetics of biologic agents unfavorably and is associated with a higher risk of treatment failure. Sleep disturbance is highly prevalent in patients with IBD, independent of disease activity, and increases the risk of relapse and chronic fatigue. Similarly, stress, particularly perceived stress rather than major life events, may trigger symptomatic flare in patients with IBD, although its impact on inflammation is unclear. Cigarette smoking is associated with unfavorable outcomes including the risk of corticosteroid dependence, surgery, and disease progression in patients with Crohn's disease; in contrast, smoking does not significantly impact outcomes in patients with ulcerative colitis, although some studies suggest that it may be associated with a lower risk of flare. The effect of alcohol and cannabis use in patients with IBD is inconsistent, with some studies suggesting that cannabis may decrease chronic pain in patients with IBD, without a significant effect of biological remission. Although these lifestyle factors are potentially modifiable, only a few interventional studies have been conducted. Trials of structured exercise and psychological therapy including mindfulness-based therapies such as meditation and yoga and gut-directed hypnotherapy have not consistently demonstrated benefit in clinical and/or endoscopic disease activity in IBD, although may improve overall quality of life.

Entities:  

Mesh:

Year:  2020        PMID: 32224703      PMCID: PMC7274876          DOI: 10.14309/ajg.0000000000000608

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

1.  COVID-19 pandemic and exacerbation of ulcerative colitis.

Authors:  Toshikuni Suda; Morio Takahashi; Yasumi Katayama; Masaya Tamano
Journal:  World J Clin Cases       Date:  2021-12-26       Impact factor: 1.337

2.  Differential Sleep Traits Have No Causal Effect on Inflammatory Bowel Diseases: A Mendelian Randomization Study.

Authors:  Min Chen; Wen-Yan Peng; Tai-Chun Tang; Hui Zheng
Journal:  Front Pharmacol       Date:  2021-11-30       Impact factor: 5.810

3.  Effect of the Coronavirus Disease 2019 Lockdown on Lifestyle Factors in Japanese Patients with Inflammatory Bowel Disease.

Authors:  Yu Nishida; Shuhei Hosomi; Koji Fujimoto; Rieko Nakata; Shigehiro Itani; Masaki Ohminami; Yuji Nadatani; Shusei Fukunaga; Koji Otani; Fumio Tanaka; Yasuaki Nagami; Koichi Taira; Noriko Kamata; Satoko Ohfuji; Yasuhiro Fujiwara
Journal:  Intern Med       Date:  2022-02-26       Impact factor: 1.282

4.  Association of Diet, Body Mass Index, and Lifestyle on the Gastrointestinal Health Risk in a Sample of Adults.

Authors:  Reyna Sámano; Fernanda Esparza-Juárez; Gabriela Chico-Barba; Erika González-Medina; Bernarda Sánchez-Jiménez; María Hernández-Trejo
Journal:  Int J Environ Res Public Health       Date:  2022-08-25       Impact factor: 4.614

Review 5.  Tryptophan-kynurenine metabolism: a link between the gut and brain for depression in inflammatory bowel disease.

Authors:  Li-Ming Chen; Chun-Hui Bao; Yu Wu; Shi-Hua Liang; Di Wang; Lu-Yi Wu; Yan Huang; Hui-Rong Liu; Huan-Gan Wu
Journal:  J Neuroinflammation       Date:  2021-06-14       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.